Last updated: June 27, 2026
Jazz Pharmaceuticals Ireland Limited sued Granules India Limited in the U.S. District Court for the District of New Jersey, case number 2:25-cv-14606. The filing appears to be an IP dispute tied to FDA drug-approval pathways (typical Paragraph IV-style allegations when brought alongside ANDA filings), but the docket extract provided here does not include the asserted patents, claims, or FDA submission details. Without the docket text and complaint specifics, a complete claim-by-claim and patent-by-patent analysis cannot be produced.
What are the key allegations in Jazz Pharmaceuticals Ireland Limited v. Granules India Limited 2:25-cv-14606?
Core issue (from case name and standard practice): patent infringement and related relief tied to a competing generic product seeking U.S. market entry.
What is missing to do a legally precise summary: the complaint or docket report section showing:
- the patent numbers asserted,
- whether the action is under 35 U.S.C. § 271(e)(2),
- the FDA application type (ANDA/BLA),
- the listed patents and Orange Book delisting/trigger theory,
- the parties to the FDA submission and product name (drug, dosage form, strength),
- the requested remedies (injunction, damages, declaratory relief).
Which patents are asserted and how many are in the estate for 2:25-cv-14606?
Featured answer: Not determinable from the information provided.
A litigation-grade patent estate analysis requires the asserted patent list (U.S. publication/patent numbers), which is not present in the user-provided prompt. Patent estate strength analysis also depends on:
- independent claim scope,
- remaining life and expiration,
- terminal disclaimer structure,
- prosecution history that impacts claim construction,
- whether patents cover active ingredient, formulation, method of use, or combination.
When does the asserted patent portfolio expire, and what is the exclusivity timeline for entry?
Featured answer: Not determinable from the information provided.
A credible “entry window” analysis needs:
- asserted patent expiration dates,
- any exclusivity blocks (5-year new chemical entity, 3-year new clinical investigation, orphan drug, pediatric exclusivity if any),
- regulatory exclusivities that interact with Hatch-Waxman timing,
- Orange Book listing status at the time of the ANDA.
How strong are Jazz’s patents in 2:25-cv-14606 compared with Granules’ likely noninfringement/invalidity defenses?
Featured answer: Not determinable from the information provided.
To evaluate strength in a way that supports litigation or investment decisions, the record must include:
- Granules’ response filings (motion to dismiss, noninfringement/invalidity theories),
- claim charts or infringement contentions,
- validity defenses such as obviousness, anticipation, written description/enablement,
- whether the case is proceeding on multiple patents with different coverage theories.
What is the procedural posture of 2:25-cv-14606 (filing date, motions, hearings, and scheduling)?
Featured answer: Not determinable from the information provided.
A procedural posture summary is not complete without:
- the complaint filing date,
- service dates,
- any docket entries such as motion to dismiss, transfer, protective order, claim construction schedule, or preliminary injunction requests,
- the status of FDA-related submissions (often required by local practice in ANDA litigation).
What is the Orange Book status of the Jazz-listed patents relevant to this case?
Featured answer: Not determinable from the information provided.
An Orange Book status section requires:
- the brand product name,
- the ANDA reference listed drug (RLD),
- the patents listed for that RLD and their expiration/pediatric/orphan status,
- whether the defendant is tied to a delisting attempt or a listed-patent infringement theory.
Does this dispute relate to Paragraph IV certifications or another FDA pathway?
Featured answer: Not determinable from the information provided.
Patent-infringement suits involving generics often align with:
- ANDA Paragraph IV certifications under 21 U.S.C. § 355(j)(2)(A)(vii),
- certification to non-infringement/invalidity for specific listed patents,
- statutory remedies under 35 U.S.C. § 271(e)(4) and 21 U.S.C. § 355(j)(5).
The prompt does not include the FDA certification language or the complaint’s statutory jurisdiction section.
What settlement or licensing scenarios typically follow for cases like this?
Featured answer: Not determinable from the information provided.
A useful settlement-analysis section must be tied to:
- whether there are existing cross-licenses,
- whether the defendant is a first filer,
- the expected launch date based on exclusivity/patent expiration,
- the number of asserted patents and the strongest “blocking” one or two.
Without the complaint’s patent and FDA details, any settlement narrative would be speculative.
How does Granules’ manufacturing/IP profile affect generic entry risk in this case?
Featured answer: Not determinable from the information provided.
A litigation-risk analysis needs:
- the product dosage form and whether it uses a protected formulation or manufacturing step,
- whether Granules’ process design avoids claimed parameters,
- any testimony in the record or prior litigations involving the same technology class.
What commercial exposure does the lawsuit create for Jazz and for Granules?
Featured answer: Not determinable from the information provided.
Commercial exposure requires:
- the brand product’s revenue and payer mix,
- the claimed product form that would launch,
- projected erosion based on entry timing and authorized generic presence,
- whether the defendant is positioned for a narrow launch (one strength/dosage) or a full portfolio.
Key Takeaways
- A litigation summary for Jazz Pharmaceuticals Ireland Limited v. Granules India Limited, 2:25-cv-14606 is not actionable from the provided prompt because it lacks the complaint’s asserted patent list, FDA pathway details, and docket entry content needed to analyze infringement, validity, timelines, or Orange Book status.
- A complete patent-estate and exclusivity timeline analysis cannot be produced without the asserted patents and their FDA-connector facts.
FAQs
- What court orders or scheduling milestones usually follow in ANDA patent cases in D.N.J.?
- How do Paragraph IV “listed patent” theories map to infringement claims under 35 U.S.C. § 271(e)(2)?
- What factors determine whether a patent is a “blocking” patent for generic launch timing?
- How do formulation vs. method-of-use claims change noninfringement defenses in generic challenges?
- What discovery items (claim charts, infringement contentions) are most outcome-determinative in Hatch-Waxman litigation?
References (APA)
- No sources were provided in the prompt, and no docket or complaint text was included to cite.
